

Supporting Information

# RNA: Packaged and Protected by VLPs

*Po-Yu Fang,<sup>a</sup> Jessica C. Bowman,<sup>a</sup> Lizzette M. Gómez Ramos,<sup>a,b</sup> Chiaolong Hsiao,<sup>c</sup> and Loren Dean Williams<sup>a,\*</sup>*

<sup>a</sup>School of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, 30332, USA, <sup>b</sup>School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA, <sup>c</sup> Institute of Biochemical Sciences, National Taiwan University, Taipei 10617, Taiwan, R.O.C.

\* Address correspondence to Loren Dean Williams.

**Reagents.** DNA oligomers were obtained from Eurofins MWG Operon, Inc. All DNA constructs were confirmed by sequencing (Eurofins MWG Operon). NZY broth media was purchased from TEKNOVA. Sec-Butanol and Chloroform and Magnesium Chloride hexahydrate were purchased from Fisher Scientific. Ferrous Ammonium Sulfate Hexahydrate was obtained from EM Science. Ammonium sulfate was purchased from ICN Biomedicals. Sucrose, RNase- and DNase-free, was purchased from Amresco. Dithiothreitol (DTT) were purchased from Research Products International Corp. (+)-sodium L-ascorbate was purchased from Sigma-Aldrich. Sodium dodecyl sulfate was purchased from Shelton Scientific, Inc. Polyethylene glycol 8000 was purchased from J. T. Baker. 30% hydrogen peroxide was purchased from Fisher Scientific. BCA protein assay kit was purchased from Thermo Scientific. Low range ssRNA ladder was purchased from New England Biolabs. Ultra-Pure SequGel was purchased from National Diagnostics. Polyallomer centrifuge tubes were purchased from Beckman Coulter. Agilent RNA 6000 Nano Kit was purchased from Agilent Technologies. Amicon® Ultra centrifugal filters (100 kDa MWCO) were purchased from Millipore. Spectra/Por® dialysis tubing (15 KDa MWCO) was purchased from Spectrum® Laboratories, Inc. All other reagents were analytical grade.

Table S1. Primers and oligomers used for construction of the Q $\beta$  CP gene<sup>a</sup>

---

Oligomer name	DNA sequence <sup>b</sup>
CP-Fwd <sup>c</sup>	5'- GTG <u>GCC ATG</u> GCA AAT TAG AGA CTG TTA CTT -3'
CP-Rev <sup>d</sup>	5'- CAC <u>CCC TAG</u> GTC AAT ACG CTG GGT TC -3'

---

Q $\beta$ CP-F1	5'- GTG GGC TCA GCT CAA TAC GCT GGG TTC AGC TGA TCA ATA GCA TCG ATC AGC AGA GGA CTA -3'
Q $\beta$ CP-R1	5'- GCT TTT GTT CGT ACA GAG CTT GCT GCT CTG CTC GCT AGT CCT CTG CTG ATC GAT GCT ATT -3'
Q $\beta$ CP-F2	5'- GCA AGC TCT GTA CGA ACA AAA GCT CGT TCC TCA TCG GTA CTA TAC TGC GTG AAC GAA AAG GTC -3'
Q $\beta$ CP-R2	5'- TTG TGA CCC ATC CGT TAC TCG CCA GGC ATA TGC TGA CGT GAC CTT TTC GTT CAC GCA GTA TAG TA -3'
Q $\beta$ CP-F3	5'- CGA GTA ACG GAT GGG TCA CAA GAA CCG TTT GCA GTG CAA GCG GTC GGG TTC TGG ATC TTA ACC TGG ACC -3'
Q $\beta$ CP-R3	5'- CCG TTT CGG TAT CTC AGC CTT CTC GCA ATC GTA AGA ACT ACA AGG TCC AGG TTA AGA TCC AGA ACC - 3'
Q $\beta$ CP-F4	5'- AAG GCT GAG ATA CCG AAA CGG TAA CAC GCT TCT CCA GCG CAG GAA CTG CAC CCG CTT GTG AAA GCG-3'
Q $\beta$ CP-R4	5'- TCT GGT CCT CAA TCC GCG TGG GGT AAA TCC CAC TAA CGG CGT TGC CTC GCT TTC ACA AGC GGG TG -3'
Q $\beta$ CP-F5	5'- ACG CGG ATT GAG GAC CAG AGT TTG TTT TCC ATC TTT CCC GAT GTT ACC TAA AGT AAC AGT C -3'
Q $\beta$ CP-R5	5'- CAC CCC ATG GGC AAA ATT AGA GAC TGT TAC TTT AGG TAA CAT CGG GAA -3'

a) Genes were constructed by recursive PCR (Bowman et al. 2012).

b) Restriction sites are underlined.

c) CP-Fwd is the forward primer, which contains an *Nco*I site.

d) CP-Rev is the reverse primer, which contains an *Avr*II site.

Table S2. Primers and oligomers used for non-viral RNA gene construction.

a-rRNA-hp <sup>a,b,c,d,e</sup>	Primer or oligomer sequence
a-rRNA-hp FWD	5'- GTG <u>GTC</u> TAG A <u>GT CCG AGT AAT TTA CGT TTT GA</u> -3'
a-rRNA-hp REV	5'- GGT <u>GGC TCA GC</u> G CGA AGA TGC TGT -3'

a-rRNA-hp oligo F1	5'- <u>TCT AGA</u> GTC CGA GTA ATT TAC GTT TTG ATA CGG TTG CGG AAC TTG CGG GGT GCC TAT TGA AGC ATG -3'
a-rRNA-hp oligo F2	5'- TCT CTA TCC GCC ACG GGC TTC CTC GTG CTT AGT AAC TAA GGA TGA AAT GCA TGT C -3'
a-rRNA-hp oligo R2	5'- <u>GCT CAG</u> CGC GAA GAT GCT GTC TTA GAC ATG CAT TTC ATC CTT AGT TAC TAA GC -3'

23S rRNA-hp hp <sup>a,b,c,d,e</sup>	Primer or oligomer sequence
23S rRNA-hp FWD	5' - GTG <u>GTC TAG A</u> GT CCG ACT AAT TTA CGT TTT GA -3'
23S rRNA-hp REV	5' - GGT <u>GGC TCA GC</u> G CGA AGA TGC TGT -3'
23S rRNA-hp oligo F1	5'- <u>TCT AGA</u> GTC CGA GTA ATT TAC GTT TTG ATA CGG TTG CGG AAC TTG C -3'
23S rRNA-hp oligo R1	5'- <u>GCA TCC ACC GTG GGC CCT TAC CAT CTT GAC</u> GCA AGT TCC GC AAC CGT AT C -3'
23S rRNA-hp oligo F2	5'- CCG AGG TCT TGA CCC CTC <u>CTT CCT CGT GCT TAG</u> TAA CTA AGG ATG AAA TG -3'
23S rRNA-hp oligo R2	5'- <u>GCT CAG CGC GAA GAT GCT GTC TTA GAC ATG</u> CAT TTC ATC CTT AGT TAC TAA GCA CGA G -3'

mRNA <sub>GFP</sub> -hp <sup>d,e</sup>	Primer or oligomer sequence
mRNA <sub>GFP</sub> -hp FWD	5'- GTG <u>GTC TAG AAT GGC TAG CAA AGG AGA AGA</u> ACT CT -3'
mRNA <sub>GFP</sub> -hp REV	5' - GGT <u>GGC TCA GC</u> G CGA AGA TGC TGT -3'

- a) The Q $\beta$  hp is highlighted in blue.
- 
- 

RBS-mRNA <sub>GFP</sub> - hp <sup>a,b,c</sup>	Primer or oligomer sequence
RBS-mRNA <sub>GFP</sub> -hp FWD	5'- GTG GTC TAG A <u>AT</u> GGC <b>TAG CAA AGG AGA AGA</b> ACT CT -3'
RBS-mRNA <sub>GFP</sub> -hp REV	5'- GGT <u>GGC TCA GCG CGA AGA TGC TGT</u> -3'
<b>RBS-mRNA<sub>GFP</sub>-hp oligo</b>	5'- TCT AGA ATA ATT TTG TTT AAC TTT AAG <b>AAG GAG</b>
F1	ATA TAC <u>CAT GGC TAG CAA AGG AGA AGA ACT CT</u> -3'

---

a-rRNA <sup>a,b,d</sup>	Primer or oligomer sequence
<b>a-rRNA FWD</b>	5'- GTG GTC TAG A <u>GT CCG AGT AAT TTA CGT TTT GA</u> -3'
<b>a-rRNA REV</b>	5'- GGT <u>GGC TCA GCG CCC GTG GCG GAT AGA GA</u> -3'

b) The spacer region highlighted in pink *italics*.

c) The ribosomal binding site (RBS), highlighted in red.

d) Overlapping recombinant RNA fragments, including a-rRNA, 23S rRNA, and GFP mRNA are highlighted in yellow.

e) XbaI/BpuI sites underlined.

## References:

Bowman JC, Azizi B, Lenz TK, Roy P, Williams LD. 2012. Preparation of long templates for RNA in vitro transcription by Recursive PCR. In *Recombinant and In Vitro RNA Synthesis: Methods and Protocols, Methods in Molecular Biology*, Vol 941 (ed. GL Conn), pp. 19-41. Springer Science, LLC.